US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

8.65

-2.4500-22.07%

Post-market: 8.30-0.3500-4.05%18:17 EDT

Volume:639.30K

Turnover:6.10M

Market Cap:426.00M

PE:-1.92

High:11.32

Open:11.21

Low:8.56

Close:11.10

52wk High:17.82

52wk Low:8.56

Shares:49.25M

Float Shares:13.84M

Volume Ratio:5.13

T/O Rate:4.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:4.10

PE(LYR):-0.05

Loading ...

Overview Company News Filings

Agomab’s ontunisertib shows positive results in Crohn’s Disease study

Agomab Reports Positive Topline Data from Stenova Open-Label Extension of Ontunisertib in Fibrostenosing Crohn’s Disease

Agomab Therapeutics Nv - Favorable Safety and Tolerability Profile Maintained Through 60 Weeks of Ontunisertib Treatment in Fscd

THOMSON REUTERS

Agomab Therapeutics Nv - Radiological Assessment Shows Trend for Fibrotic Stricture Stabilization During Treatment

THOMSON REUTERS

AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from H.C. Wainwright

Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)

Agomab Therapeutics Director Naimish Patel Files Initial Beneficial Ownership Statement

Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug

Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results

Agomab Therapeutics Nv - Agmb-447 Shows Favorable Safety and Tolerability Profile at 4.5 Mg Bid in Ipf Patients

THOMSON REUTERS

Agomab Announces Positive Phase 1 Results for Agmb-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 Inspiria Study

THOMSON REUTERS

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Adds Marino Garcia, Naimish Patel to Board

Agomab Announces Appointments of Marino Garcia and DR. Naimish Patel to Board of Directors

THOMSON REUTERS

Press Release: Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Therapeutics to Join Citi Biopharma Back to School Investor Conference

Piper Sandler Initiates Coverage on AgomAb Therapeutics With Overweight Rating

MT Newswires Live

AgomAb Therapeutics Price Target Announced at $60.00/Share by Piper Sandler

Agomab Therapeutics Nv : Piper Sandler Initiates Coverage with Overweight Rating; Target Price $60

THOMSON REUTERS

Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/AGMB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":8.65,"timestamp":1790884800000,"preClose":11.1,"halted":0,"volume":639296,"hourTrading":{"tag":"盘后","latestPrice":8.3,"preClose":8.65,"latestTime":"18:17 EDT","volume":107578,"amount":929722.42518,"timestamp":1790893064237,"change":-0.35,"changeRate":-0.040462,"amplitude":0.049711},"delay":0,"changeRate":-0.22072072072072066,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Post-Mkt","change":-2.45,"latestTime":"10-01 18:28:28 EDT","open":11.21,"high":11.3224,"low":8.56,"amount":6095142.679808,"amplitude":0.248865,"askPrice":9.59,"askSize":100,"bidPrice":8.3,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-4.51426,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790899200000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.1,"preHourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":11.1,"latestTime":"09:06 EDT","volume":2185,"amount":25474.047554999997,"timestamp":1790860001633,"change":0.4,"changeRate":0.036036,"amplitude":0.087387},"postHourTrading":{"tag":"盘后","latestPrice":8.3,"preClose":8.65,"latestTime":"18:17 EDT","volume":107578,"amount":929722.42518,"timestamp":1790893064237,"change":-0.35,"changeRate":-0.040462,"amplitude":0.049711},"volumeRatio":5.134479},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":5.134479,"shares":49248000,"dividePrice":0,"high":11.3224,"amplitude":0.248865,"preClose":11.1,"low":8.56,"week52Low":8.56,"pbRate":"4.10","week52High":17.82,"institutionHeld":0,"latestPrice":8.65,"committee":-0.980198,"eps":-4.51426,"divideRate":0,"volume":639296,"delay":0,"ttmEps":-4.51426,"open":11.21,"prevYearClose":16,"prevWeekClose":10.51,"prevMonthClose":11.1,"prevQuarterClose":11.1,"fiveDayClose":10.58,"twentyDayClose":13.66,"sixtyDayClose":12.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-30","current":-1.91615,"percent":0.950311,"low":-14.725744,"twenty":-11.126198,"median":-8.776817,"eighty":-7.627138,"high":-6.52172,"avg":-9.433798,"sd":2.193394,"marketCap":518581176},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-09-30","current":-6.851652,"twenty":-11.126198,"median":-8.776817,"eighty":-7.627138,"marketCap":518581176}],"updateTime":1790893708871},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672595097","title":"Agomab’s ontunisertib shows positive results in Crohn’s Disease study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672595097","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672595097?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:35","pubTimestamp":1790850909,"startTime":"0","endTime":"0","summary":"Agomab (AGMB) announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with Fibroste...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomabs-ontunisertib-shows-positive-results-in-crohns-disease-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomabs-ontunisertib-shows-positive-results-in-crohns-disease-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672775670","title":"Agomab Reports Positive Topline Data from Stenova Open-Label Extension of Ontunisertib in Fibrostenosing Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2672775670","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672775670?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:30","pubTimestamp":1790850641,"startTime":"0","endTime":"0","summary":"Agomab reports positive topline data from STENOVA open-label extension of ontunisertib in fibrostenosing Crohn’s diseaseAgomab Therapeutics NV reported positive topline results from a long-term extens","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL2450cg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","IE00BQXX3F31.USD","AGMB","BK4112","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BCDF","LU2210149790.SGD","IE00BKPKM429.USD","BK4007","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BQXX3D17.EUR","NDAQ","LU0314104364.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672756771","title":"Agomab Therapeutics Nv - Favorable Safety and Tolerability Profile Maintained Through 60 Weeks of Ontunisertib Treatment in Fscd","url":"https://stock-news.laohu8.com/highlight/detail?id=2672756771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672756771?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:30","pubTimestamp":1790850606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0O4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672567237","title":"Agomab Therapeutics Nv - Radiological Assessment Shows Trend for Fibrotic Stricture Stabilization During Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672567237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672567237?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:30","pubTimestamp":1790850606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0O4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167777","title":"AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167777?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:55","pubTimestamp":1790013335,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on AgomAb Therapeutics NV ADR, with a price target of $35...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARMH","DIVL","SAPH","DINT","APIE","AGMB","CVY","AADR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169130","title":"Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169130?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:50","pubTimestamp":1789998610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Charles River Labs (CRL) and AgomAb Therapeutics NV ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","BK4585","XBI","ARMH","LU0128526141.USD","LU0757428866.USD","LU1815336091.USD","BK4121","BK4007","AGMB","SAPH","CVY","BK4581","CRL","LABU","BK4530","APIE","DIVL","BK4137","HCSG","IE00BFMHRM44.USD","BK4588","AADR","LU0390134368.USD","DINT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667992624","title":"Agomab Therapeutics Director Naimish Patel Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2667992624","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667992624?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:06","pubTimestamp":1789502776,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics director Naimish Patel files initial beneficial ownership statementAgomab Therapeutics filed an initial Form 3 naming Naimish Patel as a director, marking his entry into SEC inside","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nNDL4gyF04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667957316","title":"Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667957316","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667957316?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:48","pubTimestamp":1789418880,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics said a phase 1 study for a lung disease treatment showed a reduction in a target protein, supporting the launch of a phase 2 study.The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary fibrosis, had a more than 50% reduction of pSMAD3 proteins in lung fluid cells.The dosage also had a generally favorable safety and tolerability profile, the company said. A 6mg twice-daily dose also evaluated in the study had a higher incidence of adverse events but no new specific safety signals.\"We believe that by blocking the TGF<BETA>/ALK5 pathway locally in the lung, AGMB-447 has the potential to offer a potent anti-fibrotic therapy to IPF patients,\" Chief Medical Officer Philippe Wiesel said. \"The extensive data collected in our broad Phase 1 program supports the initiation of our Phase 2 INSPIRIA study later this year.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667669545","title":"Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2667669545","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667669545?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:38","pubTimestamp":1789418311,"startTime":"0","endTime":"0","summary":"An update from AgomAb Therapeutics NV ADR ( ($AGMB) ) is now available. On September 14, 2026, Agomab Therapeutics reported topline Phase 1 data fo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/agomab-moves-inhaled-ipf-drug-agmb-447-into-phase-2-after-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/agomab-moves-inhaled-ipf-drug-agmb-447-into-phase-2-after-positive-phase-1-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAPH","AGMB","AADR","BK4007","DINT","DIVL","APIE","CVY","ARMH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667930796","title":"Agomab Therapeutics Nv - Agmb-447 Shows Favorable Safety and Tolerability Profile at 4.5 Mg Bid in Ipf Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2667930796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667930796?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUADVSHS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693754","title":"Agomab Announces Positive Phase 1 Results for Agmb-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 Inspiria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693754?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6CFCLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667696238","title":"Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2667696238","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667696238?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":"--Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high expos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361543/0/en/agomab-announces-positive-phase-1-results-for-agmb-447-in-patients-with-idiopathic-pulmonary-fibrosis-and-design-of-phase-2-inspiria-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4218","BK4007","PK","CTA","BK4181","BAL","KBWY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571437","title":"Agomab Adds Marino Garcia, Naimish Patel to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571437","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571437?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:05","pubTimestamp":1789157125,"startTime":"0","endTime":"0","summary":"Agomab adds Marino Garcia, Naimish Patel to boardAgomab shareholders appointed Marino Garcia as a non-executive director at a special meeting on Sept. 11, 2026.Dr. Naimish Patel also joined the board ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL4STDmG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","SG9999014005.SGD","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","BK4007","IE00BQXX3C00.GBP","BCDF","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571435","title":"Agomab Announces Appointments of Marino Garcia and DR. Naimish Patel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571435","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571435?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:05","pubTimestamp":1789157101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA6MDXLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571466","title":"Press Release: Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571466?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:05","pubTimestamp":1789157100,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, September 11, 2026 -- Agomab Therapeutics NV (Nasdaq: AGMB) (\"Agomab\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today anno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","IPO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809790","title":"Agomab Therapeutics to Join Citi Biopharma Back to School Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809790","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809790?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465919,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics to join Citi Biopharma Back to School investor conferenceAgomab management will attend investor conferences in New York on Sept. 10-16, 2026.Schedule includes Citi’s Biopharma Back","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL63f6xR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1506573853.SGD","IE00BSNM7G36.USD","LU1244550494.USD","LU1989772840.SGD","LU2095319765.USD","IYF","LU1064131342.USD","LU1732800096.USD","IAI","LU0234570918.USD","BK4566","LU2264538146.SGD","AGMB","IE00BKPKM429.USD","LU1244550577.SGD","IE00BN0W2V16.EUR","KBWB","LU0267386448.USD","LU1267930227.SGD","LU0795875086.SGD","LU0130102774.USD","IE00BQXX3D17.EUR","BCDF","BK4581","BK4559","LU2023251221.USD","LU2028103732.USD","TFNS","LU2357305700.SGD","LU2487616109.SGD","FTXO","LU2125154935.USD","BK4112","BK4207","NDAQ","LU0314104364.USD","LU0390134368.USD","SG9999014013.SGD","LU2417539215.USD","IE00BN0W2W23.USD","LU0528227936.USD","LU0795875169.SGD","LU1988902786.USD","LU0130517989.USD","LU0912757837.SGD","IE00BZ1G4Q59.USD","LU0106261372.USD","LU0971096721.USD","LU2133065610.SGD","LU0648001328.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662573600","title":"Piper Sandler Initiates Coverage on AgomAb Therapeutics With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2662573600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662573600?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:06","pubTimestamp":1787655998,"startTime":"0","endTime":"0","summary":"Piper Sandler Initiates Coverage on AgomAb Therapeutics With Overweight Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662384327","title":"AgomAb Therapeutics Price Target Announced at $60.00/Share by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2662384327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662384327?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:51","pubTimestamp":1787651460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662781274","title":"Agomab Therapeutics Nv : Piper Sandler Initiates Coverage with Overweight Rating; Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2662781274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662781274?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:32","pubTimestamp":1787643147,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44L0TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442456","title":"Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442456","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660442456?lang=en_us&edition=fundamental","pubTime":"2026-08-19 18:47","pubTimestamp":1787136420,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics (AGMB) has an average rating of buy and mean price target of $33.29, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}]}}